PRPH · XBRL financial data

ProPhase Labs financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PRPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	14,514	79,042	122,647	44,384	6,770	4,345
Cost of goods and services sold	9,908	37,054	51,993	28,145	6,920	2,961
Gross profit	4,606	41,988	70,654	16,239	(150)	1,384
Research and development	633	520	652	1,418	594	107
General and administrative	6,671	22,493	34,385	34,502	37,885	19,324
Total operating expenses	8,591	32,187	47,059	37,852	38,479	19,431
Operating income (loss)	(2,093)	9,801	23,595	(21,613)	(38,629)	(18,047)
Interest income	62	642	153	—	—	—
Interest expense	295	1,148	764	1,275	3,350	6,933
Other income (expense)	—	—	0	10	(18)	(174)
Income tax expense (benefit)	12	(968)	4,445	(6,018)	7,195	0
Net income (loss)	(2,125)	6,273	18,463	(16,782)	(53,364)	(14,743)
Earnings per share, basic‡ USD per share	(1.80)	4.10	11.70	(9.80)	(26.10)	(1.74)
Earnings per share, diluted‡ USD per share	(1.80)	4.00	10.20	(9.80)	(26.10)	(1.74)
Weighted average shares, basic‡ thousands of shares	1,160	1,517	1,585	1,721	2,046	8,489
Weighted average shares, diluted‡ thousands of shares	1,160	1,839	1,865	1,721	2,046	8,489

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (PRPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	6,816	8,408	9,109	1,609	678	90
Marketable securities	1,639	8,779	8,328	3,127	0	0
Accounts receivable	3,155	37,708	37,054	36,313	20,058	1,536
Inventory	3,039	4,600	3,976	3,841	1,143	70
Prepaid and other current assets	1,238	1,496	2,366	2,155	2,615	1,454
Total current assets	15,887	61,317	60,833	47,585	30,637	3,150
Property and equipment, net	3,578	5,947	7,288	—	—	2,032
Right-of-use asset	4,731	4,402	4,059	4,572	4,115	0
Goodwill	901	5,709	5,709	5,231	5,231	3,968
Total assets	31,405	89,295	87,648	91,927	63,200	59,871
Accounts payable	3,771	7,026	5,905	9,383	13,717	—
Accrued liabilities	304	300	714	1,445	1,945	1,885
Total current liabilities	6,294	15,524	16,075	20,857	32,134	53,081
Long-term debt	—	—	0	2,924	—	—
Lease liability, non-current	4,402	4,198	4,259	4,237	3,762	0
Total liabilities	20,849	30,667	24,017	42,544	55,847	56,363
Retained earnings (accumulated deficit)	(3,631)	2,642	11,753	(5,029)	(58,393)	(73,136)
Total stockholders' equity	10,556	58,628	63,631	49,383	7,353	3,508
Total liabilities and equity	31,405	89,295	87,648	91,927	63,200	59,871
Common shares outstanding (cover page)‡ thousands of shares	1,515	1,549	1,718	1,805	4,188	14,016

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.

Fiscal years (PRPH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,125)	6,273	18,463	(16,782)	(53,364)	(14,743)
Stock-based compensation	1,459	3,183	3,986	3,536	3,638	1,893
Depreciation and amortization	449	3,234	4,718	6,277	6,187	4,832
Net cash from operating activities	2,592	(13,619)	28,551	(11,348)	(17,538)	(8,344)
Net cash from investing activities	(1,016)	(19,666)	(2,077)	(1,369)	2,422	920
Proceeds from issuing common stock	—	—	—	0	7,594	3,558
Share repurchases	—	917	2,152	588	0	—
Dividends paid	—	4,546	9,353	0	—	—
Net cash from financing activities	9,990	35,127	(26,023)	5,757	14,185	6,836
Net change in cash	6,382	1,842	451	(6,960)	(931)	(588)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.